Wolfe Research lowers iRhythm stock price target on valuation By Investing.com

Wolfe Research cut iRhythm Technologies' price target to $180 from $200 but reiterated an Outperform rating, implying roughly 40% upside from the $129.16 share price. The firm still sees premium valuation support based on 2027 revenue and high-teens growth, while iRhythm also posted Q1 2026 results that beat expectations with EPS of -$0.43 versus -$0.66 consensus and revenue of $199.4 million versus $194.08 million. The news is constructive overall, though the lower target tempers the tone.

Analysis

IRTC’s setup is less about a single-quarter beat and more about a credibility reset: when a growth medtech name prints above consensus while still showing operating leverage, the market tends to re-rate the duration of growth before it fully re-rates the multiple. The key second-order effect is that the stock can outperform peers even if its absolute valuation stays above the group, because the market is paying for a rarer combination of accelerating growth and narrowing loss trajectory. That tends to pull in momentum and quality-growth capital that had previously been sitting on the sidelines.

The bigger implication for competitors is that premium diagnostics platforms with recurring data streams should keep screening better than single-product hardware or lower-growth monitoring peers. If iRhythm continues to show that revenue growth can stay in the high-teens while margins improve, it forces investors to revisit the “watchlist only” basket in small-cap healthcare and reward businesses that can prove reimbursement stability plus utilization expansion. The supply-chain angle is modest, but any supplier leveraged to consumables or sensors tied to monitoring volumes should see incremental demand confidence if the growth narrative persists.

The main risk is that this is a multiple story masquerading as a fundamentals story. If the next 1-2 quarters show any deceleration in order flow, payer friction, or gross margin slippage, the stock can de-rate quickly because the market has already granted it a premium growth franchise discounting far into 2027. Near term, the trade is more sensitive to analyst revisions and management commentary than to headline earnings alone; over 3-6 months, the real catalyst is whether guidance proves that the beat was a clean read-through rather than timing noise.

Consensus may be underestimating how much further the stock can move if the company keeps compounding into a scarcer-growth bucket while the broader medtech group remains low-teens. The contrarian risk, however, is that the valuation argument starts to outrun the evidence: at this size, a small miss in revenue cadence or a pause in multiple expansion can erase a large portion of the upside quickly. In other words, the opportunity is real, but it is a narrow path that depends on execution staying consistently above the bar.

Key Decisions for Investors

• Go long IRTC on pullbacks over the next 1-3 weeks, with a tactical target of the revised sell-side valuation band; use a tight stop if post-earnings momentum fails to hold, because the stock is likely to trade on revision velocity rather than absolute fundamentals.
• Pair trade: long IRTC / short a basket of slower-growth small-cap medtech names over 1-3 months. The thesis is that premium-growth names will continue to attract scarce capital while lower-growth peers remain stuck at depressed revenue multiples.
• If options liquidity is sufficient, buy 3-6 month calls or call spreads in IRTC to express upside with defined downside; this fits a name where the catalyst is multiple expansion plus estimate revisions, not just next-quarter earnings.
• Avoid chasing at strength unless management commentary confirms sustained high-teens growth and margin improvement. A single-quarter beat is not enough to justify paying ahead of evidence if payer or utilization trends soften.
• Use any post-rally consolidation to re-enter rather than selling immediately; the risk/reward improves if the market digests the new target and waits for the next operational proof point, likely over the next 1-2 reporting cycles.